Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of new combinations of treatments, including novel drugs and standard therapies, for patients with advanced or metastatic non-small cell lung cancer NSCLC. This multicenter, open-label study focuses on participants with stage IV NSCLC, specifically assessing combinations involving rilvegostomig with platinum-based chemotherapy and with or without ramucirumab. The study includes a sub-study with safety and dose expansion phases to identify the recommended dose and assess treatment activity. Participants with squamous and non-squamous NSCLC will receive intravenous infusions of rilvegostomig combined with standard chemotherapy drugs such as cisplatin, carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel. Some participants will also receive ramucirumab as part of their treatment. The sub-study consists of a Part A safety run-in to evaluate dose levels and a Part B expansion phase to further study the treatments. Participants are randomized into different treatment arms depending on their cancer histology. During the study, participants will undergo monitoring for adverse events, dose-limiting toxicities, and tumor response over approximately 46 months. Assessments include measuring objective response, duration and time to response, disease control, progression-free survival, overall survival, and various blood drug concentration parameters. Tumor tissue samples are required for evaluation, and safety and tolerability are closely monitored throughout the treatment period.
Actively Recruiting
Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.
Actively Recruiting
Researchers are exploring new treatment options for people with advanced colorectal cancer that has spread or cannot be removed by surgery. This cancer type, affecting the colon or rectum, sometimes involves problems with the bodys DNA repair system called dMMR or a condition called MSI. These issues can cause cancer cells to rely on a protein called Werner helicase to survive. Blocking this protein might help stop cancer growth with less harm to healthy cells. This Phase 2 study evaluates a drug named VVD-133214 that blocks Werner helicase, combined with pembrolizumab, an immunotherapy drug approved to help the immune system attack cancer cells. Participants in this trial will receive oral VVD-133214 along with pembrolizumab given by intravenous infusion every three weeks. The study compares this combination to pembrolizumab alone to find the best dose of VVD-133214 and to assess whether the combination works better. Participants will receive VVD-133214 as long as it remains helpful without causing serious side effects, while pembrolizumab treatment will continue for up to two years. Participants may stop treatment at any time. During the trial, participants will have regular visits for tests, scans, and health check-ups to monitor how their cancer responds and to track any new or worsening medical problems. After stopping treatment, follow-up visits will occur 30 days after the last VVD-133214 dose and 100 days after the last pembrolizumab dose. Long-term follow-up visits will continue every 90 days as long as participants agree to remain in the study. The main outcome measured is the progression-free survival rate at six months, with safety and other response measures also monitored throughout up to about 36 months.
Actively Recruiting
Researchers are evaluating the efficacy and safety of AZD1163, a novel bispecific antibody, in adults with moderately-to-severely active rheumatoid arthritis RA. AZD1163 targets enzymes involved in protein citrullination, which leads to the production of harmful antibodies in RA. This Phase II, randomized, double-blind, placebo-controlled study focuses on adults with positive anti-citrullinated peptide antibodies ACPA who are already receiving standard treatments. Participants will be randomly assigned to one of four groups to receive subcutaneous injections of either one of three doses of AZD1163 or a placebo, all combined with their standard care including conventional synthetic disease-modifying antirheumatic drugs csDMARDs or tumor necrosis factor inhibitors TNFi with or without csDMARDs. The treatment period lasts 24 weeks, followed by a safety follow-up phase of 28 weeks. During the study, participants will undergo assessments including measures of disease activity using scores such as DAS28-CRP at 12 weeks. Additional evaluations will monitor response criteria, clinical disease activity indices, and the pharmacokinetics and immunogenicity of AZD1163 up to 24 weeks and during follow-up. Safety and efficacy will be closely monitored throughout the treatment and follow-up periods, with total participation lasting approximately 52 weeks.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of subcutaneous anifrolumab injections compared to placebo in adults with moderate to severe Idiopathic Inflammatory Myopathies IIM, including polymyositis PM and dermatomyositis DM. This Phase III, multicenter, randomized, placebo-controlled, and double-blind study adds anifrolumab or placebo to participants standard of care treatment to assess overall disease activity. Participants receive either anifrolumab or a matched placebo by subcutaneous injection once weekly for 52 weeks while continuing their standard treatments. After this period, all participants have the option to receive open-label anifrolumab weekly for an additional 52 weeks. This design allows researchers to compare the effects of anifrolumab against placebo and then observe longer-term effects when all receive anifrolumab. Throughout the study, participants undergo regular assessments including the Total Improvement Score TIS at 52 weeks as the main outcome. Additional evaluations include muscle strength testing, corticosteroid dosage monitoring, skin disease activity, and itch severity up to 52 weeks. Safety and disease activity improvements for both PM and DM participants are closely monitored. The study lasts up to approximately two years, including both blinded and open-label treatment phases.
Actively Recruiting
Healthy Volunteer
Researchers are investigating the effects of aquatic aerobic exercise combined with cognitive tasks on cognitive function and other health outcomes in older women aged 60 to 75. The study aims to determine whether adding cognitive tasks to aquatic exercise provides additional cognitive benefits compared to conventional aquatic exercise alone or no intervention. This randomized, single-blinded, three-arm trial is sponsored by the Federal University of Pelotas and focuses on aging-related changes in cognition and physical health. Participants are randomly assigned to one of three groups an aquatic aerobic exercise program with cognitive tasks, a conventional aquatic aerobic exercise program, or a control group. The exercise programs last 12 weeks with two sessions per week on non-consecutive days. The aquatic aerobic exercises involve interval training using movements such as butt kick, frontal kick, cross-country skiing, and stationary running with intensity guided by a perceived exertion scale. The cognitive tasks target various cognitive domains and are performed during active recovery phases in the combined group. During the study, participants undergo assessments at the start, after the 12-week intervention, and again at a 12-week follow-up. These include tests measuring cognitive function like the Digit Span Test and Controlled Oral Word Association Test, as well as evaluations of physical function, cardiovascular health, and psychosocial factors such as depressive symptoms and quality of life. The study tracks adherence to exercise intensity and progression in cognitive tasks. The goal is to evaluate whether both exercise programs improve health outcomes compared to no intervention, with added cognitive benefits expected from combining exercise with cognitive tasks.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a Phase 3b, randomized, double-blind for ages 60-79 and open-label for ages 40-59, multicenter study to evaluate the safety and immune response of the Butantan Dengue vaccine in adults aged 40 to 79 years. The study compares the humoral immune response of elderly participants 60-79 years to that of adults aged 40 to 59 years, including those with or without previous dengue exposure. The goal is to assess whether the vaccines immune response in the elderly is not inferior to that in younger adults. Participants receive a single dose of the Dengue 1,2,3,4 attenuated vaccine or placebo, with three study groups elderly receiving vaccine, adults receiving vaccine, and elderly receiving placebo. The vaccine dose contains an approximate concentration of 103.0 PFU of each attenuated dengue serotype virus. The study will last one year to evaluate immune response duration and monitor adverse events. Surveillance for dengue, chikungunya, and Zika virus infections will occur throughout the study. Participants will undergo blood tests to measure antibody responses at Day 1, Day 42 7 days, and Day 364 28 days after vaccination. Safety will be monitored through reports of adverse reactions up to Day 22 3 days and throughout the study. Participants will be contacted periodically by phone, electronic means, and home visits. Researchers will analyze neutralizing antibody seroconversion and track serious adverse events, ensuring participants health and vaccine safety over the year-long follow-up.
Actively Recruiting
Healthy Volunteer
Researchers are comparing two methods for assessing the risk of dental caries tooth decay in children aged 7 to 11 years. The study aims to evaluate whether an elaborate, individualized risk assessment using the International Caries Classification and Management System ICCMS provides better guidance for treatment and follow-up than a simpler method based only on past dental caries experience. This is a randomized, double-blind clinical trial conducted over two years at the Pediatric Dentistry Clinic of the Federal University of Pelotas. Participants will be randomly assigned to one of two groups one group will receive dental caries treatment and maintenance guided by the multivariate ICCMS risk assessment, while the other group will be treated based on their caries experience alone using WHO criteria. Treatments and follow-up intervals will be tailored according to the initial risk assessment method assigned. The study includes evaluations at baseline, 12 months, and 24 months. During the study, parents will complete questionnaires about their childs diet, general and oral health quality of life, and medical history. Children will undergo clinical exams to assess caries presence and activity using the simplified ICDAS system. Researchers will track new caries lesions requiring operative intervention as the primary outcome and will also assess quality of life changes from baseline to the end of treatment. Data will be analyzed to compare the two risk assessment approaches over the 24-month period.
Actively Recruiting
Researchers are studying the long-term safety and effectiveness of pembrolizumab MK-3475 in participants with advanced tumors or blood cancers who were part of previous pembrolizumab-based studies. This extension study includes participants currently receiving treatment or in follow-up from parent trials. It consists of three phases the First Course Phase, Survival Follow-up Phase, and Second Course Phase, depending on the participants status at the end of their previous study. Participants may receive pembrolizumab alone or combined with standard of care treatments, lenvatinib, or other study drugs like olaparib and MK-4280, delivered mainly by intravenous infusion or oral capsules. Dosing schedules vary, including pembrolizumab administered every 3 or 6 weeks for up to 35 or 17 doses depending on the phase. Some participants may take lenvatinib orally daily, timed with pembrolizumab infusions, while others may receive investigational combination therapies or standard care treatments according to their parent studys protocol. During the study, participants will have regular infusions or oral dosing and be monitored over several years for overall survival and other outcomes like progression-free survival and adverse events. Researchers will assess safety and efficacy for up to approximately 10 years, with detailed tracking of side effects and treatment discontinuations. Study visits and assessments will be conducted to evaluate organ function, disease status, and any treatment-related effects throughout the study duration.
Actively Recruiting
Researchers are conducting a Phase III clinical trial to evaluate the effects and safety of pumitamig in patients with triple-negative breast cancer TNBC who have locally recurrent inoperable or metastatic disease and are ineligible for PDL1 therapy due to PD-L1 negative status. This trial compares pumitamig combined with chemotherapy to placebo combined with chemotherapy, using a randomized, double-blind design to measure progression-free survival and overall survival. Participants will be randomly assigned to one of two groups one receiving pumitamig plus a physicians choice of chemotherapy and the other receiving a placebo plus the same chemotherapy options. Chemotherapy regimens include paclitaxelnab-paclitaxel, gemcitabine plus carboplatin, or eribulin, administered by standard intravenous infusion. The treatment continues until disease progression, intolerable side effects, withdrawal, death, or trial end. After treatment, participants enter a safety follow-up period for up to 90 days and a survival follow-up phase lasting until death, withdrawal, loss of contact, or sponsor decision. During the study, participants undergo screening lasting up to 28 days before treatment begins. Assessments include tumor measurement using RECIST criteria, tissue sample collection excluding certain biopsy types, and performance status evaluation. Researchers track multiple outcome measures such as tumor response rates, quality of life scores, adverse events, and survival rates over periods up to approximately 49 months. This comprehensive monitoring ensures participant safety and collects data on the trial drugs impact compared to placebo with chemotherapy.